Hong Kong Stock Movement: IVD MEDICAL falls 15.01%, subsidiary's reduction in holdings triggers market confidence crisis

Hong Kong Stock Movement

IVD MEDICAL fell 15.01%. Based on recent news,

1. On November 28, IVD MEDICAL announced that it spent HKD 7.7236 million to repurchase 1.187 million shares, with a repurchase price of HKD 6.37-6.53 per share. Although buybacks are generally seen as positive news, the market reacted poorly, and the stock price failed to find effective support.

2. On November 28, Xinhua Medical announced that its wholly-owned subsidiary Hua Tuo International plans to sell no more than 5% of its shares in IVD MEDICAL through open market transactions. This move was interpreted by the market as a lack of confidence in IVD MEDICAL's future development, leading to a significant drop in the stock price.

3. On November 28, IVD MEDICAL's announcement showed that as of the market close that day, the stock price was HKD 6.53, up 0.93%, with a trading volume of 2.702 million shares and a turnover of HKD 17.5688 million. However, investment banks have shown little interest in the stock, with no ratings given in the past 90 days, leading to a lack of market confidence. The pharmaceutical commercial II industry has shown weak performance recently, resulting in insufficient market confidence.

Stocks with High Trading Volume in the Industry

China National Pharmaceutical Group rose 1.50%. Based on recent news,

1. On November 28, China National Pharmaceutical Group announced that Zhao Bingxiang resigned as a non-executive director and chairman of the board, with Jin Bin taking over as chairman and authorized representative. This news attracted market attention, causing fluctuations in the stock price.

2. On November 28, Feng Rongli resigned as a non-executive director and member of the board's compensation committee, and Li Ying was nominated as a non-executive director. This personnel change further affected market sentiment.

3. In the past 90 days, investment banks have primarily rated China National Pharmaceutical Group as a buy, with a target average price of HKD 23. CITIC Securities' latest research report gave a buy rating, boosting market confidence. The pharmaceutical commercial II industry has shown stable performance recently, with significant capital inflow.

Yao Shi Bang fell 1.85%, with a turnover of HKD 23.59 million, and no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, this stock shows significant volatility, and specific reasons need further observation.

Baiyunshan fell 0.27%. Based on recent key news:

1. On November 28, Baiyunshan announced that Guangzhou Pharmaceutical signed a basic asset delivery confirmation letter with Xingzheng Asset Management, selling accounts receivable with a book value of RMB 442 million and receiving a purchase price of RMB 440 million. This transaction helps to revitalize asset stock and improve liquidity, affecting the stock price negatively.

2. On November 28, Baiyunshan's subsidiary Guanghua Pharmaceutical signed a land storage compensation agreement with the Tonghe Street Office, with total compensation and land transfer rewards amounting to approximately RMB 450 million. This move is beneficial for revitalizing existing assets and aligns with long-term development goals, having a certain impact on the stock price.

3. On November 28, Baiyunshan held a performance briefing for the third quarter of 2025, reporting a year-on-year revenue growth of 9.74% for the first three quarters. Despite the performance growth, the market reaction was below expectations, leading to stock price fluctuations. The traditional Chinese medicine industry has shown stable performance recently, with significant capital inflow Stocks Ranked Among the Top by Market Capitalization in the Industry

Shanghai Pharmaceuticals rose by 0.17%. Based on recent news,

1. On November 28, Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefu Pharmaceutical Co., Ltd.'s Tramadol Hydrochloride Injection passed the consistency evaluation of generic drug quality and efficacy. This drug is mainly used for the treatment of moderate to severe pain and is expected to gain a larger market share and medical insurance support, driving up the stock price. Source: Zhitong Finance

2. On November 28, Shanghai Pharmaceuticals announced that Tramadol Hydrochloride Injection passed the consistency evaluation of generic drugs, with research and development costs of approximately RMB 1.52 million. Drugs that pass the consistency evaluation will receive greater support in medical insurance payments and procurement by medical institutions, enhancing market share. Source: CaiLianShe

3. On November 28, Shanghai Pharmaceuticals announced that its Tramadol Hydrochloride Injection passed the consistency evaluation of generic drug quality and efficacy and received the "Drug Supplement Application Approval Notification" issued by the National Medical Products Administration. This drug was developed by Grunenthal GmbH and was first launched in Germany in 1977. Source: 36Kr The pharmaceutical industry has recently shown stable performance, with increased policy support